Recurrent myocarditis in the context of Behçet’s disease: a case report

Ana Moura 1*, Mariana Saraiva 1, João Matos Costa 2, Kevin Domingues 1, and Vítor Martins 1

1Department of Cardiology, Hospital Distrital de Santarém, Av. Bernardo Santareno, 2005-177 Santarém, Portugal; and 2Department of Internal Medicine, Hospital Distrital de Santarém, Av. Bernardo Santareno, 2005-177 Santarém, Portugal

Received 4 November 2020; first decision 25 November 2020; accepted 6 May 2021

Background
Behçet’s syndrome is a multisystemic vasculitis of unknown aetiology. Cardiac involvement is rare, with described prevalence between 1% and 46%, with pericarditis, valvular insufficiency, intracardiac thrombosis, and eventually sinus of Valsalva aneurysms being the most common findings. Although previously reported, myocarditis is a very rare complication of Behçet’s syndrome.

Case summary
A 26-year-old man, smoker but otherwise healthy, was admitted to the emergency department with atypical chest pain, with no radiation, relation to efforts, position or deep inspiration, and dyspnoea, since the day before. His physical examination was unremarkable, including no fever, tachycardia, or pericardial friction rub. Electrocardiogram (ECG) revealed an early repolarization pattern, with no changes noted in subsequent exams. He had elevation of inflammatory parameters and an increased high-sensitivity troponin level of 3300 ng/L. Transthoracic echocardiography (TTE) was unremarkable. Coronary angiography showed no coronary stenosis. A presumed diagnosis of non-complicated viral myocarditis was established. The patient’s condition improved with acetylsalicylic acid as needed and colchicine and he was discharged after 3 days. Cardiac magnetic resonance was performed, showing late epicardial enhancement in the apical segment of the lateral wall, supporting the diagnosis of myocarditis. Four months later, the patient returned with recurrence of chest pain. Additionally, he also complained of fever, odynophagia, and otalgia since the previous week. Oropharyngeal examination revealed tonsillar pillars aphthosis. The ECG was similar to the previous and TTE was normal. Bloodwork revealed once again elevation of inflammatory parameters and elevation of troponin. Recurrent myocarditis was diagnosed. Treatment with ibuprofen, colchicine, and antibiotic therapy was started with no significant improvement. After a more thorough physical examination, an ulcerated scrotal lesion, a left buttock folliculitis, and an axillary hidradenitis were found, which, according to the patient, were recurrent in the last year. Accordingly, the diagnosis of Behçet’s syndrome with mucocutaneous and cardiac involvement was established. The patient was kept on colchicine and was also started on immunosuppressive therapy with corticosteroids and azathioprine, with resolution of the symptoms in the following day. A positron emission tomography (PET) was performed 2 days after discharge and showed a higher myocardial uptake in the left ventricular basal segments and both papillary muscles. Prednisolone tapering was started after 2 months, while maintaining azathioprine. At 1-year follow-up, the patient remained asymptomatic. A re-evaluation PET was performed, showing no images suggestive of metabolically active disease in the myocardium.
Discussion

This case highlights the importance of awareness of this rare but potentially serious entity and reinforces the significance of aetiology investigation in cases of recurrent myocarditis. It also shows the success of immunosuppressive therapy in a context where the optimal management is still considerably uncertain.

Keywords

Myocarditis • Behçet disease • Auto immune disease • Case report

Learning points

Our case:

• Emphasizes the importance of aetiology investigation in cases of recurrent myocarditis.
• Raises awareness for Behçet’s syndrome as a possible rare aetiology underlying myocarditis.
• Demonstrates the relevance of aggressive immunosuppressive therapy with high-dose glucocorticoids and azathioprine in a field where the optimal therapy scheme is unknown.

Introduction

Behçet’s syndrome is a multisystemic vasculitis of unknown aetiology.1 Cardiac involvement is rare, with described prevalence between 1% and 46%.2–4 Cardiac abnormalities reported in the literature include pericarditis, myocarditis, endocarditis, intracardiac thrombosis, endomyocardial fibrosis, coronary arteritis with or without myocardial infarction, and coronary arteries or sinus of Valsalva aneurysms.4

Case presentation

A 26-year-old man, smoker but otherwise healthy, was admitted to the emergency department with atypical chest pain with no radiation and no relation to efforts, position or deep inspiration; associated with dyspnoea, since the day before. There was no history of previous flu-like symptoms, fever, or gastrointestinal symptoms. On examination, the patient was haemodynamically stable, afebrile, and eupnoeic; no pericardial friction rub and no cardiac murmurs were noted. Electrocardiogram (ECG) revealed an early repolarization pattern with no changes noted in subsequent exams (Figure 1A). His blood test results showed neutrophilic leucocytosis (white blood cell

Timeline

| Time                                | Events                                                                 |
|-------------------------------------|------------------------------------------------------------------------|
| 1 Year prior to presentation        | Recurrent buttock folliculitis and axillary hidradenitis               |
| Day 0                               | Admission to the emergency department with chest pain and dyspnoea since the previous day |
| Day 1                               | Coronary angiography showed no coronary stenosis or aneurysms. Diagnosis of presumed myocarditis. Treatment with aspirin as needed and colchicine |
| Day 3                               | Discharged from hospital                                               |
| 1 month after initial presentation  | Cardiac magnetic resonance imaging showed late epicardial enhancement in the apical segment of the lateral wall, consistent with the diagnosis of myocarditis |
| 4 months after initial presentation | Return to the emergency department with recurrence of persistent chest pain with no pleuritic characteristics, fever, sore throat, odynophagia, and otalgia with a week of duration. Oropharyngeal examination revealed tonsillar pillars aphthosis with exudate. Recurrent myocarditis with possible bacterial tonsillitis was diagnosed, and the patient was hospitalized. Ibuprofen, colchicine, and antibiotic therapy was started |
| 4 months and 2 days after initial presentation | Persistence of fever, chest pain, and elevation of inflammatory markers despite treatment. Thorough physical exam noting an ulcerated scrotal lesion, left buttock folliculitis, and axillary hidradenitis. Diagnosis of Behçet’s syndrome with mucocutaneous and cardiac involvement was established. The patient was kept on colchicine and was also started on immunosuppressive therapy with corticosteroids and azathioprine |
| 4 months and 13 days after initial presentation | Discharge from hospital                                               |
| 4 months and 15 days after initial presentation | A positron emission tomography (PET) with fludeoxyglucose (FDG) showed a more intense myocardial uptake in the left ventricular basal segments, as well as in both papillary muscles |

Continued
Continued

| Time | Events |
|------|--------|
| 6 months after presentation (2 months after initiation of immunosuppressant therapy) | Weaned from steroids |
| 1 year after presentation (6 months after initiation of immunosuppressant therapy) | Follow-up PET-FDG showed no images suggestive of metabolically active disease. The distribution of FDG in the myocardium presented as a diffuse pattern, without individualization of hypermetabolic foci |

### Table 1: Cases of cardiac involvement in Behçet disease—review of the literature (1990–2019)

| First author, year | Type of cardiac involvement | Treatment | Outcome |
|--------------------|-----------------------------|-----------|---------|
| Marzban et al., 2008¹ | Severe aortic insufficiency | Corticosteroids; surgery | Complete remission |
| Kusuyama et al., 2002² | Aortic insufficiency and aneurysm of sinus of Valsalva | Surgery | Complete remission |
| Vanhaleweyk et al., 1998³ | Intracardiac thrombosis (right atrium and ventricle and left ventricle) | Anticoagulant, corticosteroids, cyclophosphamide | Complete remission |
| Basaran et al., 2000⁴ | Intracardiac thrombosis | Anticoagulant; corticosteroids; surgery | Relapse (surgical excision) |
| Yakut et al., 2007⁵ | Intracardiac thrombosis | Anticoagulant, corticosteroids; cyclophosphamide | Complete remission |
| Baykan et al., 2001⁶ | Anticoagulant, corticosteroids, cyclophosphamide | | Complete remission |
| Cevik et al., 2009⁷ | Anticoagulant | | Complete remission |
| Noureddine et al., 2004⁸ | Corticosteroids | | Complete remission |
| Kirali et al., 1998⁹ | Surgery | | Complete remission |
| Chiari et al., 2008¹⁰ | Anticoagulant; corticosteroids; immunosuppressants | | Complete remission |
| Dogan et al., 2007¹¹ | Anticoagulant; corticosteroids; immunosuppressants | | Complete remission |
| Darie et al., 2005¹² | Right ventricular thrombus and endomyocardial fibrosis | Surgery | Complete remission |
| Soulami et al., 1996¹³ | — | — | Death |
| Kosar et al., 2005¹⁴ | Acute myocardial infarction | Colchicine | Partial remission |
| Beyranvand et al., 2009¹⁵ | | Corticosteroids | Partial remission |
| Rolland et al., 1993¹⁶ | Left ventricular and coronary artery aneurysms | Surgery | Complete remission |
| Marashi et al., 2005¹⁷ | Left ventricular pseudoaneurysm | Surgery | Complete remission |
| Nakata et al., 1995¹⁸ | Right atrial vegetation | Corticosteroids | Complete remission |
| Kwon et al., 2006¹⁹ | Pericarditis and cardiac tamponade, coronary arteries | Colchicine; corticosteroids; surgery | Complete remission |
| Jagadeesh et al., 2014²⁰ | Pericarditis | Corticosteroids; methotrexate; pericardio-centesis. Patient intolerant to azathioprine, 6-mercaptopurine, mycophenolate, thalidomide | Complete remission |
| Lewis et al., 1964²¹ | Myopericarditis | Aspirin | Complete remission |
| Satoshi et al., 2014²² | Giant-cell myocarditis | Corticosteroids; azathioprine; ICD | Death |
| Felix et al., 2016²³ | Myocarditis and dilated cardiomyopathy | Colchicine, AINE's; corticosteroids; azathioprine | Partial remission |
| Jagadeesh et al., 2014²⁰ | Dilated cardiomyopathy | Beta-blocker, IECA and diuretics; CRT-D | Partial remission |
| Scheuble et al., 2003²⁴ | — | Corticosteroids | Partial remission |
| Mustafa et al., 2010²⁵ | — | Corticosteroids; azathioprine | Complete remission |
| Kaatz et al., 1998²⁶ | — | — | — |

References provided in the Supplementary material online.
count of $13.3 \times 10^9/L$—normal range $4–10.0 \times 10^9/L$), a normal C-reactive protein (0.68 mg/dL—normal value $< 0.05$ mg/dL), mild elevation of erythrocyte sedimentation rate (ESR) of 20 mm/h (normal value $< 14$ mm/h), and an increased initial high-sensitivity troponin level of 3300 ng/L (normal value $< 34.2$ ng/L). Transthoracic echocardiography (TTE) was unremarkable, with no pericardial effusion. Invasive coronary angiography showed no coronary stenosis or aneurysms (Figure 2). A presumed diagnosis of non-complicated viral myocarditis was established. The patient’s condition improved with aspirin as needed and colchicine, and he was discharged after a 3-day in-hospital stay with complete resolution of his symptoms. Cardiac magnetic resonance (Figure 3) was performed 1 month after presentation, with identification of an area of late epicardial enhancement, located in the apical segment of the lateral wall, supporting the diagnosis of myocarditis. Four months later, the patient returned to the emergency department with recurrence of chest pain. Additionally, he also complained of fever, sore throat, odynophagia, and otalgia since the previous week. Oropharyngeal examination revealed the tonsillar pillars aphthosis with exudate, while his otoscopy was normal. The ECG was similar to the one of the previous hospitalization.
**Figure 2** Invasive coronary angiography showing no coronary stenosis.

**Figure 3** Cardiac magnetic resonance with identification of an area of late epicardial enhancement, located in the apical segment of the lateral wall, reinforcing the diagnosis of myocarditis.
Bloodwork revealed once more elevation of inflammatory markers (white blood cell count of 14.0 × 10⁹/L, C-reactive protein of 4.02 mg/dL, and ESR of 140 mm/h) and elevation of troponin (2828 ng/L). There was a normal platelet count (338 × 10⁹/L—normal range 150–400 × 10⁹/L) and coagulation parameters (INR: 1.07—normal range 0.88–1.12). Recurrent myocarditis was diagnosed, and the patient was hospitalized. Treatment with ibuprofen and colchicine was started and, given the possibility of concomitant bacterial tonsillitis, he was also initiated on antibiotic therapy. Despite treatment, there was no significant improvement, with persistence of fever and elevation of inflammatory markers. After a more thorough physical examination, an ulcerated scrotal lesion (Figure 4), a left buttock folliculitis, and axillary hidradenitis were found, which, according to the patient, were recurrent for the last year. Accordingly, the diagnosis of Behçet’s syndrome with mucocutaneous and cardiac involvement was established. The patient was kept on colchicine 1 mg per day, and was also started on...
immunosuppressive therapy with corticosteroids (initial 1 g 3-day pulse of methylprednisolone followed by prednisolone 1 mg/kg daily) and azathioprine (2.5 mg/kg daily) with resolution of the symptoms on the following day. A positron emission tomography (PET) with fluorodeoxyglucose (FDG) was performed 2 days after discharge (Figure 5) and showed a higher myocardial uptake in the left ventricular basal segments, as well as in both papillary muscles with no other foci of abnormal uptake. Prednisolone tapering was started after 2 months, while remaining on long-term azathioprine (100 mg daily) and colchicine (1 mg daily) therapy. At 1-year follow-up, the patient remained asymptomatic, with complete resolution of ulcerated and aphthous lesions and with no recurrence of chest pain. A re-evaluation PET was performed at that time, showing a uniform capture of FDG in the myocardium, with no images suggestive of metabolically active disease.

**Discussion**

Behçet’s syndrome was first described in 1937 and it is classified as an inflammatory vascular systemic disease with an aetopathogenesis that remains unknown. As there is a lack of a universally recognized pathognomonic test, Behçet’s syndrome diagnosis is primarily based on clinical criteria. Recurrent mucocutaneous lesions (oral aphthosis), skin lesions (papulopustular lesions, erythema nodosum, and skin ulcers), ocular findings (uveitis/retinitis/hypopyon-iritis), and reactivity to needle prick test are the most common clinical findings. Currently, the International Criteria for Behçet Disease (ICBD), reviewed in 2013, are recommended as a guide for diagnosis, with a score $\geq 4$ being supportive of Behçet’s syndrome with estimated sensitivity of 93.9% and specificity of 92.1%. In this case, the patient had an ICBD score of 6.

The real prevalence of cardiac involvement in Behçet’s syndrome remains unknown as it can be asymptomatic. The reports in the literature are very discrepant, with prevalence between 1% and 46%. It is estimated to be the first manifestation of the disease in $<2\%$ of the cases. The mean age at diagnosis in this specific group is 29.7 ± 9.9 years and cardiac lesions are predominantly reported in men and in the first years of the disease’s diagnosis, characteristics that are in conformity with our case.

In the largest review available, in 52 Behçet’s syndrome patients with cardiac involvement, pericarditis was the most common form (38.5%), followed by valvular insufficiency (26.9%), intracardiac thrombosis (19.2%), myocardial infarction (17.3%), and endomyocardial fibrosis (7.7%). In other series sinus of Valsalva aneurysms and aortitis were the most frequently reported cardiac complications. Myocarditis related to Behçet’s syndrome is very rare, with diagnosis in only 1.2% of the autopsies performed in a cohort of Japanese patients with Behçet’s syndrome and described in some series as isolated cases, with some developing heart failure in the context of dilated cardiomyopathy.

Although veins are more frequently affected by vasculitis in Behçet’s syndrome, arteries of any size can also be involved, which seems to be the most prevalent underlying mechanism of cardiovascular manifestations. Necrotizing leucocytoclastic or polymorphonuclear, obliterative perivasculitis, and lymphocytic cell infiltration of capillaries, arteries, and vasa vasorum are the main pathologic features in affected tissues during acute phases. In advanced stages, a significant fibrosis and scarring may develop.

Little is known about the optimal treatment for the patients with Behçet’s syndrome. It is usually determined by the degree of systemic manifestations and involves a therapeutic combination of colchicine, corticosteroids, and/or other immunosuppressants. The level of uncertainty increases in the context of Behçet’s syndrome with myocarditis, with no guidelines established for this entity so far. In the cases of reported Behçet’s syndrome with cardiac involvement in a presumed context of vasculitis (Table 1) the majority of the authors report the use of a combination of colchicine, corticosteroids, and azathioprine. Although there is no data in the literature about the recurrence rate of myocarditis in Behçet’s syndrome, in the previously cited review article, relapse of symptoms is documented in 35% of the patients with pericarditis.

In this case, anti-inflammatory therapy and colchicine only were clearly insufficient to control symptoms related to myocarditis, supporting an important role for stronger immunosuppressants in this kind of presentation.

Annual mortality in Behçet’s syndrome varies between 2% and 4%. Studies show that overall survival in the patients with cardiac involvement is significantly worse than in those without, with a documented 5-year survival rate of 83.6% vs. 95.8% ($P = 0.03$), respectively.

**Conclusions**

This case highlights the importance of awareness of this rare but potentially serious entity and emphasizes the significance of aetiology investigation in cases of recurrent myocarditis. It also shows the success of immunosuppressive therapy in a context where the optimal management is still considerably uncertain.

**Lead author biography**

Ana Moura, MD, is currently a third year resident in Hospital Distrital de Santarém, Portugal. She received an MD degree from Instituto Ciências Biomédicas Abel Salazar—University of Porto in 2016.

**Supplementary material**

Supplementary material is available at European Heart Journal - Case Reports online.

**Slide sets:** A fully edited slide set detailing this case and suitable for local presentation is available online as Supplementary data.

**Consent:** The authors confirm that written consent for submission and publication of this case report including images and...
associated text has been obtained from the patient in line with COPE guidance.

**Conflict of interest:** None declared.

**Funding:** None declared.

**References**

1. Kalayciyan A, Zouboulis C. An update on Behçet’s disease. *J Eur Acad Dermatol Venereol* 2007;21:1–10.
2. Bennis A, Noureddine M, Azzouzi L, Soulimi S, Benamour S, Chraibi N. Cardiac manifestations of Behçet disease. *Ann Med Interne (Paris)* 1996;147:126–129.
3. Godeau P, Wechsler B, Maaouni A, Fagard M, Herreman G. Cardiovascular involvement in Behçet’s disease. *Ann Dermatol Venereol* 1980;107:741–747.
4. Satoshi M, Akira T, Hirofumi Z. Behçet’s disease complicated by giant-cell myocarditis. *Intern Med* 2014;53:1721.
5. International Team for the Revision of the International Criteria for Behçet’s Disease (ITR-ICBD). The International Criteria for Behçet’s Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. *J Eur Acad Dermatol Venereol* 2014;28:338–347.
6. Bletry O, Mohattane A, Wechsler B, Beaufils P, Valère P, Petit J et al. Cardiac manifestations of Behçet’s disease 12 cases. *Presse Med* 1988;17:2388–2391.
7. Geri G, Wechsler B, Thi Huong DL, Isnard R, Piette J-C, Amoura Z et al. Spectrum of cardiac lesions in Behçet disease: a series of 32 patients and review of the literature. *Medicine* 2012;91:25–34.
8. Yoshikawa K, Hori H, Fukunaga S, Taya E, Aoyagi S. Aortic root replacement in Behçet disease. *Asian Cardiovasc Thorac Ann* 2007;15:521–523.
9. Lakhapal S, Tani K, Lie JT, Katoh K, Ishigatsu Y, Ohokubo T. Pathologic features of Behçet’s syndrome: a review of Japanese autopsy registry data. *Hum Pathol* 1985;16:790–795.
10. Melek K, Sana S. Cardiac and vascular complications of Behçet disease in the Tunisian context: clinical characteristics and predictive factors. *Adv Rheumatol* 2018;58:32.
11. Felix N, Fabian C, Russell B, Louise MB. A rare case of Behçet disease with generalised myositis, cardiomyositis and necrotising fasciitis. *BMJ Case Rep* 2016;2016:2015211983.
12. Feridun K, Ibrahim S, Hakan G. Acute myocardial infarction with normal coronary arteries in a young man with the Behçet’s disease. *Int J Cardiol* 2005;355–357.
13. Owlia M, Mehrpoor G. Behçet’s disease: new concepts in cardiovascular involvement and future direction for treatment. *ISRN Pharmacol* 2012:2012.
14. Gulen H, Robin C, Dongisk B. 2018 Update of the EULAR recommendations for the management of Behçet’s syndrome. *Ann Rheum Dis* 2018;77:808–818.